Plasma homovanillic acid in the prodromal phase of schizophrenia. (Q52081363)

21 April 2018

http://europepmc.org/abstract/MED/10704954

title

Plasma homovanillic acid in the prodromal phase of schizophrenia. (English)

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

0 references

Sumiyoshi T

1

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

Kurachi M

2

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

Kurokawa K

3

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

Yotsutsuji T

4

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

Uehara T

5

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

Itoh H

6

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

Saitoh O

7

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

language of work or name

English

0 references

publication date

1 March 2000

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

published in

Biological Psychiatry

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

volume

47

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

issue

5

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

page(s)

428-433

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

cites work

Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Plasma homovanillic acid and treatment response in a large group of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

A theory of dopamine function and its role in cognitive deficits in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Interrelationships between plasma homovanillic acid and indices of dopamine turnover in multiple brain areas during haloperidol and saline administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Plasma homovanillic acid concentration and the severity of schizophrenic illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Early detection and intervention for initial episodes of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

The effects of stress on central dopaminergic neurons: possible clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Etiologic heterogeneity of the psychoses: is there a dopamine psychosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Haloperidol response and plasma catecholamines and their metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

The Effect of Mental Stress on Catecholamines, their Metabolites and Plasma Renin Activity in Patients with Essential Hypertension and in Healthy Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Direct determination of homovanillic acid release from the human brain, and indicator of central dopaminergic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Studies of catecholamine metabolism in schizophrenia/psychosis--I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Studies of catecholamine metabolism in schizophrenia/psychosis--II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Prodromal symptoms in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Recent life stressors and biological markers in newly admitted psychotic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Phase I study of a new antianxiety drug, buspirone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Neuropsychological function in schizophrenia. Selective impairment in memory and learning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Serum homovanillic acid levels in schizophrenic patients and normal control subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Effect of mental stress on plasma homovanillic acid in healthy human subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Differential effects of mental stress on plasma homovanillic acid in schizophrenia and normal controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Influence of renal clearance on peripheral homovanillic acid measurements in healthy subjects and schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

Lack of effect of laboratory-provoked anxiety on plasma homovanillic acid concentration in normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900186-9

10.1016/S0006-3223(99)00186-9

7 January 2021

Identifiers

DOI

1 reference

21 April 2018

http://europepmc.org/abstract/MED/10704954

1 reference

21 April 2018